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Aging western societies are facing an increasing prevalence of chronic inflammatory 
and degenerative diseases for which often no effective treatments exist, resulting in 
increasing health-care expenditure. Despite high investments in drug development, 
the number of promising new drug candidates decreases. We propose that preclinical 
research in non-human primates can help to bridge the gap between drug discovery and 
drug prescription. Translational research covers various stages of drug development of 
which preclinical efficacy tests in valid animal models is usually the last stage. Preclinical 
research in non-human primates may be essential in the evaluation of new drugs or 
therapies when a relevant rodent model is not available. Non-human primate models for 
life-threatening or severely debilitating diseases in humans are available at the Biomedical 
Primate Research Centre (BPRC). These have been instrumental in translational research 
for several decades. In order to stimulate European health research and innovation from 
bench to bedside, the European Commission has invested heavily in access to non- 
human primate research for more than 20  years. BPRC has hosted European users 
in a series of transnational access programs covering a wide range of research areas 
with the common theme being immune-mediated inflammatory disorders. We present 
an overview of the results and give an account of the studies performed as part of 
European Union Framework Programme (EU FP)-funded translational non-human pri-
mate research performed at the BPRC. These data illustrate the value of translational 
non-human primate research for the development of new therapies and emphasize the 
importance of EU FP funding in drug development.
Keywords: overview, eU projects, non-human primates, preclinical research, translational research
iNtrODUctiON
A broadly recognized concern that formed the basis of the restructuring of the Life Sciences and 
Health program funded by the European Commission (EC) is the poor translation of scientific 
discoveries into effective treatments for patients (1–3). Potential new therapeutics are often target 
specific and may not react with the homologous target in rodents. Combined with the limited 
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predictive value of rodent disease models for the human disease 
(4, 5), non-human primates may be the species of choice for pre-
clinical testing. Furthermore, accumulating evidence shows that 
the aging of the immune system under the influence of chronic 
latent infections, such as herpesviruses (CMV, EBV), is an 
important driver of chronic inflammatory disorders via mecha-
nisms that are not present in SPF rodents (6). Especially in the 
field of immune-mediated inflammatory disorders, non-human 
primates may help to bridge the gap between animal model and 
patient (5, 7). Non-human primate models’ may also be valuable 
for reverse translational research into the causes underlying the 
high attrition of new therapies (8).
Europe houses several primate research centers with the 
facilities and expertise for preclinical research; the Biomedical 
Primate Research Centre (BPRC) in Rijswijk, The Netherlands 
is one of the largest.1 Non-human primate research is expensive 
and requires specialized infrastructure. Academic investigators 
and small- to medium-sized (SME) biotech companies often have 
difficulties to cover the high costs for proof-of-concept studies in 
non-human primates.
The EC has recognized the importance of preclinical non-
human primate research and the high costs associated with it. 
Transnational access (TA) programs to non-human primate 
research have been installed under various EU Framework 
Programmes (FP) providing essential funds that helped investi-
gators with the development of new therapeutic entities or with 
testing new scientific hypotheses.
Research in non-human primates falls under the EU Directive 
on the protection of animals used for scientific purposes that was 
entered into force in 2010.2 The directive explicitly states that 
“to the present state of scientific knowledge, the use of non-human 
primates in scientific procedures is still necessary in biomedical 
research,” but that “the use of non-human primates should be 
permitted only in those biomedical areas essential for the benefit of 
human beings, for which no other alternative replacement methods 
are yet available.”
Against these backgrounds, we have analyzed 20 years of EU 
FP-funded translational research studies in non-human primates 
performed at the BPRC. In our analyses, we have included 47 
studies performed as part of EU FP-funded translational research 
into the pathogenesis and treatment of disorders caused by the 
immune system performed between 1996 and 2015.
The results of EU FP-funded studies are often not published 
within the project period and are thus not visible in the CORDIS 
database, “the European Commission’s primary public reposi-
tory and portal to disseminate information on all EU FP-funded 
research projects and their results in the broadest sense.”3 In addi-
tion, the results of the preclinical non-human primate research 
may not be published at all, when study results are inconclusive 
or negative. By presenting an overview of EU FP-funded TA to 
non-human primate models for immune-mediated and neuro-
degenerative preclinical research performed at BPRC, we want 
1 www.bprc.nl. 
2 http://eur-lex.europa.eu/eli/dir/2010/63/oj. 
3 http://cordis.europa.eu/projects/home_en.html. 
to provide insight into these processes. By including unpublished 
studies in our analysis, we provide a different view on the con-
tribution of non-human primate research to the development of 
new therapies as compared to an analysis of the drug registration 
files (9, 10). Such analyses underestimate the value of non-human 
primate preclinical research, as drugs that are not registered 
because of failure in non-human primate studies are usually not 
included.
OvervieW OF 20 YeArs NON-HUMAN 
PriMAte trANsNAtiONAL Access 
PrOGrAMs
The BPRC has been involved in EU FP-funded preclinical research 
in non-human primate models for chronic and infectious dis-
eases for more than 20 years. The first TA program started under 
the third FP: Biomedical Primate Research Centre: non-human 
primates as models for human biology and disease (BPRC), 
CORDIS database reference CHGE940071. Together with two EU 
Concerted Actions (references MR4*0276 and BMH11531), this 
multiannual program has resulted in a number of publications 
(11–23). However, information on studies that were performed 
as part of these programs, but were not published, is lacking. We 
therefore focus our review on the period between 1996 and 2015. 
In this period, BPRC has hosted five EU FP-funded TA programs 
and has participated in four EU FP-funded consortia dedicated 
to preclinical non-human primate research on chronic, degenera-
tive, and infectious diseases (Table 1).
In the 1980s and 1990s, treatment for prevention of organ 
transplant rejection was a major driver of immunosuppressive 
drugs development. For decades, (non-human primate) organ 
transplantation has been the favored model for immunosup-
pressive drug evaluation, as the target of the immune response 
is known, namely, the grafted organ (kidney) or tissue (skin). 
Development of models for autoimmune-mediated inflamma-
tory disease (AIMID) has gradually replaced transplantation 
as the model of choice for immunosuppressive drug discovery. 
Often, the efficacy of a new drug needs to be established first 
in a relevant model, and new treatments do not need to be 
developed for each specific disease. The available non-human 
primate models of AIMID, collagen-induced arthritis (CIA), 
and experimental autoimmune encephalomyelitis (EAE) are 
now used as prototype models for a broader spectrum of 
(auto)immune-mediated diseases in the human population. 
This seems justified, as recent genome-wide association stud-
ies show that pathways of immune activation are common 
to a wide range of diseases (26). Many treatments are at first 
instance indicated for diseases affecting a large number of 
patients, such as rheumatoid arthritis (RA). Drugs successfully 
used for high prevalence indications are subsequently tested for 
diseases affecting smaller numbers of patients or for indications 
where the relevance of the target in the disease is less well 
established.
Projects submitted for execution under the TA were always 
reviewed by a User Selection Panel, which consisted of interna-
tional experts in the fields of research covered by the TA and 
tAbLe 1 | Overview of transnational access programs and dedicated consortia.
Acronym reference cOrDis tA/consortium Framework 
programme
Period title
CFIT BMH4960127 TA 4 1996–1998 EU Centralized Facility for ImmunoTherapy Evaluation (24)
BPRC-LSF FMGE950024 TA 4 1996–1999 BPRC large scale facility: non-human primates as models for human biology 
and disease (24)
PCDD HPRI-CT-2001-00150 TA 5 2001–2004 Non-human primates as Preclinical Models Facility of Chronic and 
Degenerative Diseases in humans (25)
PRIMOCID 26155a TA 6 2006–2010 Primate models of chronic and immune-based diseases
PRIMOCID-II 262443a TA 7 2011–2015 Primate models of chronic and infectious diseases-IIb
– BMH4972131 Consortium 4 1997–2000 Targeted anti-CD40 monoclonal antibodies for treatment of multiple sclerosis
EUPEAH QLRI-CT-2002-02758 Consortium 5 2003–2008 Glucocorticoid hormone programing in early life and its impact on adult 
health
TRIAD 281493 Consortium 7 2012–2014 Tolerance restoration in autoimmune diseases by selective manipulation of 
the CD28 costimulatory pathwayc
PRIMOMED 606084 Consortium 7 2014–2015 Use of PRIMate MOdels to support translational MEDicine and advance 
disease modifying therapies for unmet medical needsd
aPRIMOCID programs were part of the Research Infrastructures of EUPRIM-Net (http://www.euprim-net.eu/home.htm) under FP 5 and FP6.
bhttp://www.bprc.nl/en/eu-sponsored-transnational-access.
chttps://www.triad-cd28.eu/.
dhttp://www.primomed.fp7sme.eu/.
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principal investigators from the BPRC. Criteria for selection 
were scientific relevance and quality, the necessity for testing 
in non-human primates and the likelihood that research objec-
tives could be reached. Selected projects were subsequently 
submitted to the institute’s ethics committee for review of the 
experimental design and procedures. The complete costs for 
purchase of genetically typed monkeys, housing and care, and 
all experimental procedures of elected projects were covered by 
the TA or the consortia.
Research topics for TA programs were obviously a reflection of 
the societal challenges and public interest of their times. For the 
“EU Centralized Facility for ImmunoTherapy Evaluation” (acro-
nym: CFIT) program, which ran from 1996 to 1998 [see Table 1 
(24)], two focuses were identified by the User Selection Panel, 
namely (1) interference with immune activation, with a strong 
focus on the induction of immune tolerance, and (2) application 
of somatic gene therapy and/or stem cells in chronic inflam-
matory diseases. In addition, part of the activities was aimed at 
the development and improvement of non-invasive methods to 
assess disease severity and the development of in vitro parameters 
for prediction of the in vivo outcome of immunotherapy.
The follow-up TA program, “Non-human primates as 
Preclinical Models Facility of Chronic and Degenerative Diseases 
in humans” (PCDD), was advertised as a program to initiate a 
European Immune Tolerance Network (25). Submitted projects 
were in line with this ambition, indicating that within the EU 
research community indeed the consensus was that immune 
tolerance was the ultimate aim for the prevention of organ 
graft rejection or possibly even for (auto)immune diseases. 
Intervention in immune activation has remained an important 
topic over the years. This was also the aim of three of the four 
dedicated consortia (Table 1) in which BPRC has participated. 
Immunosuppression is the next best option after disease preven-
tion and/or cure.
In the two subsequent PRIMOCID programs, non-human 
primate somatic gene therapy research was no longer in fashion 
and stem cell therapy became a hot topic. The focus of the two 
PRIMOCID programs shifted further toward understanding 
disease mechanisms and to apply more refined means of immu-
nosuppression, by interfering with single pathways. The aim of 
establishing immune tolerance has been gradually left, among 
others due to observations in monkeys and humans that the 
pathogen-educated primate immune system may be relatively 
resistant to tolerance induction strategies (5, 27).
The rationale to include the four EU FP-funded consortia in 
which BPRC participated, stems from the fact that these consortia 
had similar aims as the TA programs, the only difference being 
that BPRC was not the coordinator. The consortia “anti-CD40 in 
multiple sclerosis,” TRIAD, and PRIMOMED were all aimed at 
the development of immunosuppressive therapies in non-human 
primate EAE and CIA models. Within PRIMOMED, there 
was also a project testing a new therapy for neurodegenerative 
diseases, which used the MPTP-induced marmoset model of 
Parkinson’s disease. The aim of EUPEAH was to establish the 
impact of pre-natal dexamethasone exposure on health param-
eters in adulthood.
AcHieveMeNts
In the period between 1996 and 2015, a total of 38 in vivo EU 
FP-funded studies were executed in TA programs (see Table 2). 
From 35 of the projects, the original applicant data could be 
analyzed. One user obtained access twice (in two different 
programs, on two different models, 7  years apart), resulting 
in 34 different users. Of those 34 users, 25 were male, 9 were 
female, and they originated from 12 different EU Member States 
or associated countries (associated countries are eligible for EU 
FP funding).
FiGUre 1 | causes and/or reasons underlying unpublished studies. 
The size of the circle reflects the total number of studies in that category. 
*Results of one pilot study referred to in review paper (58), and results from the 
second pilot study are mentioned on SME website (http://www.s-target.com/). 
**Results of one study published only in a non-peer-reviewed paper (59).
tAbLe 2 | Overview of all fully executed in vivo studies under the indicated eU FP per disease model and publications.
total # studies eAe ciA Kidney tx PD infectious  
diseases
Other
executed Accepted/published
CFIT 12 8 2 (28) 3 (29–31) 5 (32–35) 2 (36)
BPRC-LSF 3 3 3 (37–39)
PCDD 7 3 2 (40, 41) 2 1 2 (42)
PRIMOCID 9 5 2 (43, 44) 2a (45) 5 (46, 47)
PRIMOCID-II 7 3 2 (48, 49) 1 3a 1 (50)
Dedicated consortia 9 6 7 (28, 51–54) 1 (55) 1a
Total 47 28 18 7 6 3 3 10
aManuscript(s) in preparation.
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Nine in  vivo EU FP-funded studies were executed at BPRC 
as part of consortia coordinated outside the BPRC. A total of 
47 EU FP-funded studies included in this analysis have resulted 
in 28 peer-reviewed papers reporting primary data. One paper 
contains data obtained from two studies (28), and two papers 
present primary data from one study (29, 30). The substantial 
delay between publication of papers and the closure of the 
projects is exemplified by the fact that four publications are still 
in preparation, with one paper reporting data collected under 
the PRIMOCID-I program, which was closed in 2010 (Table 2).
The effects of the indicated foci of each of the programs 
are reflected in the list of publications. The focus in CFIT on 
interference with immune activation/tolerance is evidenced by 
references (28, 32–36) and the focus on somatic gene therapy/
stem cells by (29–31). The development and improvement of 
non-invasive methods has resulted in three additional publica-
tions (20, 56, 57). The focus of the PCDD program on tolerance 
induction is unfortunately not reflected in publications, illustrat-
ing the already mentioned difficulty in tolerance induction in the 
pathogen-educated primate immune system. Four of the seven 
studies have remained unpublished, of which two were aimed at 
tolerance induction. The two subsequent PRIMOCID programs 
did not have predefined foci and were therefore a reflection of 
the general interest of the research community. In one study, the 
capacity of human induced pluripotent stem cells (iPS) to repair 
MS-like brain lesions in marmosets was tested, resulting in a pub-
lication (48). The second study describes a pilot study to set up 
an Alzheimer’s disease model in marmosets (50). Other research 
themes were understanding disease mechanisms and refinement 
of immunosuppression, yielding four publications (43–46, 49).
The results of 15 studies were not published as peer-reviewed 
papers. Figure 1 illustrates the complex interplay of causes for 
studies not resulting in the publication. The most common reason 
is absence of a significant beneficial effect, or sometimes even a 
detrimental effect of the treatment/therapy under study (nine 
studies). Non-human primate studies are usually small sized and 
insufficiently powered for detecting small effects or significant 
effects only in a part of the animals. When a study is then also 
hampered by technical problems (Figure  1), firm conclusions 
can often not be drawn, which precludes publication in the 
peer-reviewed literature. Two reasons underlying five additional 
unpublished studies are that four studies were designed as pilot 
studies, and one of them, together with the second study failed in 
follow-up in vivo testing. The unpublished pilot studies were all 
performed during the first four TA programs. It should be noted 
that unpublished studies are always accounted for in project 
reports to the EC.
Publication of negative studies is a hotly debated issue. We 
strongly believe that important lessons can be learned from 
negative results, providing that the study was executed without 
technical problems. It is well possible that the targeted process 
may be less relevant in a primate model than in lower species. 
We believe that this is the essence of translational research (7). 
Studies involving non-human primates are often the end-stage 
of a long development process, where the candidate therapy has 
passed several selections. It is important that the reason why a 
treatment fails at a late development stage is examined and that 
results are published. The lack of publishable results does not nec-
essarily mean that the study was not valuable. Often the absence 
of adverse effects, even when positive effects of the therapy/
treatment were not obtained, will motivate researchers to further 
develop the drug or choose another disease where the targeted 
process may be more relevant.
One of the recommendations of the EUPRIM-Net II funded 
workshop on Alternative methods for the use of non-human 
primates in biomedical research was that negative results should 
be published (60). The EC also strongly advocates public dis-
semination of the results of funded projects in grant agreements. 
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To  cover the costs of open access publication for studies per-
formed under FP7, the EC has installed a support program.4 
BPRC always requires that researchers of submitted projects are 
willing to publish the results. The reality is that mandatory publi-
cation of negative or inconclusive results would pose a barrier to 
participate in TA programs.
sPiN-OFF
Although most studies were aimed at the efficacy evaluation of 
new therapies, the spin-off of these studies has reached further 
than the immediate study aims. Body fluids, tissues, organs, 
and/or cells collected from in vivo studies, EU FP-funded and 
privately funded, are frequently used at a later stage for ex vivo 
analyses. These analyses drive further investigations into patho-
genic pathways. Examples of such analyses are the description of 
anti-vimentin antibodies in kidney transplantation (61), a still 
unresolved problem in transplant patients; description of the lack 
of association of FOXP3 as a regulatory marker in non-human 
primate transplantation (62); evaluation of IL-1β expression in 
brain tissue of rhesus macaques with EAE, compared to in MS 
patients (63), and other descriptive analysis of larger sets of 
tissues obtained during various studies (64, 65).
Furthermore, results from in  vivo studies may be used to 
develop or optimize biomarkers for disease (18, 19), pathological 
hallmarks, and/or mechanisms (66–68). During the CFIT pro-
gram, one of the aims was to develop non-invasive diagnostic 
parameters, which has resulted in a number of important 
developments for in vitro and ex vivo analysis (20, 56, 57). These 
refinements are implemented in subsequent studies.
Starting under the first TA program under FP3, a new model 
for multiple sclerosis has been developed, EAE in common 
marmosets (18, 23). The model has been extensively refined 
throughout subsequent TA programs and used for preclinical 
efficacy testing (28, 37, 40, 43, 44, 49, 51–53). The close clini-
cal and pathological approximation of the model to the human 
neurological disease on which it had been projected (multiple 
sclerosis) has been recognized. This is evidenced by the fact that 
the model was also the model of choice for preclinical efficacy 
testing outside EC-funded research (69–73).
trANsLAtiONAL vALUe 
OF eXecUteD PrOJects
To answer the question if EC funding of preclinical non-human 
primate research helps to bridge the gap between drug discovery 
and drug prescription, a number of issues need to be considered. 
Some of the projects were submitted by academic researchers, 
merely to investigate pathogenic mechanisms or the clinical 
potential of therapies that are not (yet) applicable for human use 
(29–31, 36–41, 43, 49, 51), and other projects were submitted 
by medium-sized Pharma companies. Whether development of 
such drugs would have continued also without access to the TA, 
cannot be established.
4 https://postgrantoapilot.openaire.eu/#home. 
The translational value of the 15 unpublished studies is vari-
able. As discussed, two studies failed in follow-up testing, and the 
studies were not able to signal the subsequent problems. From 
three other studies, the drug under investigation entered the TA 
programs via other routes as well, and that drug is still a candidate 
for clinical testing. One reason as a cause for a study not being 
published in a peer-reviewed paper is its success for the SME. 
In the case of one unpublished pilot study (Figure 1), the SME 
continued with the research and provided proof of therapeutic 
principle in an efficacy study. The technology was licensed to a 
pharmaceutical company.5 This leaves another nine studies, all 
for unique drugs or cell therapies, which have not resulted in any 
economic spin-off.
However, most certainly, EU FP funding has helped to speed 
up the development of a number of drugs or therapies, although it 
is still too early for most of them to have reached the clinic. Below 
illustrative examples are listed.
The clinical development of anti-CD40 monoclonal antibody 
as immunosuppressive treatment has benefited from several EU 
FP-funded programs. In its various forms, and under its various 
owners, several papers were published, with (23, 52, 53, 59) and 
without (74–77) EU funding. Currently, a clinical grade deim-
munized version of the tested antibody is under development 
by FF Pharma, and phase I clinical trials have been successfully 
completed.6
The proprietary anti-CD28 monoclonal antibody (54, 55) is 
currently in phase I clinical trials.7 An international EU FP-funded 
consortium was formed, to advance this therapy toward the clinic, 
and this has been very successful.
Anti-CD20 monoclonal antibodies have been used in patients 
already, but its mechanism of action had not yet been fully 
resolved. The mechanism has been studied in one EC-funded 
study (44), as well as privately funded studies (73, 78, 79).
Amgen has bought Micromet, the company that developed the 
anti-IL2 receptor monoclonal antibody developed (46). Whether 
this antibody is still under development by Amgen has not been 
disclosed on the AMGEN website.
The impact of a posttranslational modification of IgG4 
molecules exchanging half-molecules (one heavy chain with 
its attached light chain), so-called Fab arm exchange, was first 
described in an EU FP-funded study in the rhesus monkey 
model for myasthenia gravis (42). This discovery has impacted 
research with therapeutic monoclonal antibodies in many ways, 
and nowadays, IgG4 antibodies are often stabilized to prevent 
unwanted Fab arm exchange (80). Genmab exploits this principle 
to generate bispecific antibodies.8
cONcLUsiON
In the period of 20 years spanning this review, 47 studies were 
performed with EC funding. These studies are often a reflec-
tion of the interest of the research community of their times. 
5 http://www.s-target.com/. 
6 http://www.ffpharma.com/2014/index.php/clinical-trials/pg102-03. 
7 http://ose-immuno.com/en/portefeuille-de-produits/fr104/. 
8 http://www.genmab.com/duobody/technology. 
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Important for determining the value of non-human primate 
research in drug development is both the number of studies 
with positive findings and negative findings. The 47 studies 
have resulted in 28 peer-reviewed papers, with 4 more papers 
in preparation, mostly describing important new findings, 
but in 1 case, negative results were also published (32). Also, 
more then 10 papers describing ex vivo analyses of materials 
obtained during these studies have been published. Fifteen 
studies did not result in a publication, primarily because of 
absence of a beneficial effect. Although we are contractually 
bound not to disclose details of these studies, this review ena-
bles us to picture the complex interplay of causes that prohibit 
the publication of studies. The most obvious one is the lack 
of positive results, but additional risk factors are technical 
problems and the pilot type of studies. Technical problems 
cannot always be avoided, but the inherent responsibilities 
resulting from EC funding for TA, dictate that funding should 
be directed toward established models, with a clear testable 
hypothesis.
Another possible cause for the absence of an effect may of 
course also indicate that the drug is just not effective and the 
development for human use may be reconsidered. For these cases, 
a database of negative results would certainly benefit the value of 
the money spent.
The importance of EU FP funding is undisputed, as 95% of 
these studies could not have been performed without it. It has lead 
to many important findings, but within this period of 20 years, it 
has not (yet) resulted in drugs being available for patients.
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